the following updates info has all been included i
Post# of 9144
(Total Views: 398)
Posted On: 10/08/2019 11:15:09 PM
the following updates info has all been included in the board info for a long time
as Mits noted the nih grant app for this GBS project was submitted Jan 2019.
from Update on N-Assay Pretest Development 1-16-19 posted by Eudius: "The current focus of this NIH grant application is on Group B Streptoccus (GBS). We are currently discussng Urinary Tract Infection (UTI) diagnostic test development with other companies and plan to proceed concurrently with studies for that development .
NanoLogix has also agreed to fund an existing laboratory in Houston currently in use as a clinical laboratory for the medical group associated with Dr Jonathan Faro. This lab will be crucial to the testing of patient samples during the upcoming study.
Although our partner has a very successful record of receiving grants for development, neither NanoLogix nor our partner in the GBS pretest development can guarantee that the NIH grant will be awarded for this project. With that in mind, nanoLogix is continuing to pursue alternative funding for both the GBS and UTI pretest development, including international sale or licensing of the FlatPack extended-life petri plate packaging technology.
Further updates will occur as warranted."
from the below update its apparent the GBS grant was still being pursued.
No mention is made in the last update of the gbs grant,which may or not be instructive.
We know from previous posted dd that its common for grant apps to be rejected the 1st time around in this competitive grant environment and that the applicable NIH committee often makes suggestions to improve the grant proposal.
The 6 month timeline for approval would've been july 2019,at which time the grant may have been approved,and the other items noted in the updates for disclosure have not been completed yet
OR the grant was initially rejected,with the common procedure of the NIH committee suggesting improvements to the proposal,in which case either NNLX and or the CA company are working on the NIH suggested improvements to the proposal
OR the grant was rejected in July and the CA companies cost benefit analysis of their precious time re further pursuit was negative, in which case the CA company working on the GBS grant may have withdrawn. Although the n-assay has much merit, big companies,with sometimes a short attention time and money span,could retire from the situation and thus no mention in the august update- but we dont know this-silence in the last update re this does not necessarily mean this
partly because the net revenue approach is another useful approach,which can be perfectly complementary, just as NNLX said in the 1-19 update, "NanoLogix is continuing to pursue alternative funding for both the GBS and UTI pretest development, including international sale or licensing of the FlatPack extended-life petri plate packaging technology"
and the 8-19 update, "NanoLogix is discussing with domestic and international investment groups, and is seeking additional interested parties."
As I alluded to in a previous post, the new net revenue approach may have more than one purpose,and one of those purposes may be to light a fire(push forward) other negotiations, which may be stalled or stalemated,in order to put pressure on the other party in any such stalled negotiations. I have no inside info re this,but that would be a fairly frequent purpose,which does not take away from the legitimacy of the net revenue approach (a common method) as another realistic avenue to finance the necessary tests.
updates below
Posted On: 04/02/2019 12:44:58 PM
Posted By: Kachingpdx1
Update on N-Assay
Overview and Potential in Multi-billion Diagnostics Market
NanoLogix is pleased to add an important PowerPoint Presentation update to our January 2019 statement of coordinated bacteria pretest development activity with two Biotechnology firms.
Posted On: 08/21/2019 6:53:03 AM
Posted By: willtheoak
like a sleeping purple dinosaur, nanologix has awakened
NanoLogix Seeks $3 Million For Expansion and Development
Offers Net-Revenue Share of N-Assay Bacteria Diagnostic
NanoLogix is discussing with domestic and international investment groups, and is seeking additional interested parties, for an investment offer of a net-revenue interest share of the N-Assay Bacteria Diagnostic and its planned associated Pretest. In exchange for an investment of up to $3 million, NanoLogix proposes a five-year 3-5% net-revenue sharing arrangement beginning with the proposed marketing rollout of the N-Assay in 2021, following planned patient studies in Houston. The funds are to be used for company expansion, development, production and marketing for the N-Assay, Pretest, and FlatPack petri plate technologies. There is no stock issuance or dilution involved with the funding proposal.
A PowerPoint presentation on the N-Assay Bacteria Diagnostic is included to illustrate just some of the advantages of the technology. The PowerPoint includes information on upper respiratory infections (URI), general sepsis infections, and sepsis infections related to infant low-birth weights. In future updates there will be information on shares of the diagnostic market devoted to each of those, and other infections for which configurations of the N-Assay are being explored.
Posted On: 04/02/2019 12:44:58 PM
Posted By: Kachingpdx1
Update on N-Assay
Overview and Potential in Multi-billion Diagnostics Market
NanoLogix is pleased to add an important PowerPoint Presentation update to our January 2019 statement of coordinated bacteria pretest development activity with two Biotechnology firms.
The PowerPoint Presentation can be viewed on The NanoLogix website at: http://nanologix.com/
The purpose of the pre-test use with the N-Assay is to have a pre-test that will indicate the presence of a specific bacteria with minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required.
Further updates will occur as warranted.
Update on N-Assay Pretest Development 1-16-19 posted by Eudius
NIH Grant Application Submitted for
Pre-test Development Study
NanoLogix is pleased to provide this update to our August 2018 statement of coordinated development activity with a California-based Biotechnology firm. The planning for a research study for development of a rapid pre-test for use with the patented Nanologix N-Assay bacteria diagnostic is proceeding, with staff selections completed, letters of recomendation from noted medical authorites written, and the submission last week of the grant application for the study to the NIH by our Silicon-Valley partner. The research study is planned for two major Houston hospitals, funded from both Federal Grants and a raise of investment capital.
The personnel agreeing to participate in the study are seven MDs, two research nurses, two microbiologists, at least two laboratory technicians, and the CEO of the California Biotechnology company. NanoLogix personnel and the CEO of the Biotechnology company have signed a mutual non-disclosure agreement limiting what can presently be revealed but once funding has been obtained and the study registered with the FDA and initiated, the identity of the pre-test development company should be available as public knowledge.
The purpose of the pre-test use with the N-Assay is to have a pre-test that will indicate the presence of a specific bacteria with minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required. This development will significantly reduce reliance upon broad-spectrum antibiotics, which contribute to the major worldwide problem of the development of antibiotic-resistance for many bacteria.
The current focus of this NIH grant application is on Group B Streptoccus (GBS). We are currently discussng Urinary Tract Infection (UTI) diagnostic test development with other companies and plan to proceed concurrently with studies for that development.
NanoLogix has also agreed to fund an existing laboratory in Houston currently in use as a clinical laboratory for the medical group associated with Dr Jonathan Faro. This lab will be crucial to the testing of patient samples during the upcoming study.
Although our partner has a very successful record of receiving grants for development, neither NanoLogix nor our partner in the GBS pretest development can guarantee that the NIH grant will be awarded for this project. With that in mind, nanoLogix is continuing to pursue alternative funding for both the GBS and UTI pretest development, including international sale or licensing of the FlatPack extended-life petri plate packaging technology.
Further updates will occur as warranted.
as Mits noted the nih grant app for this GBS project was submitted Jan 2019.
from Update on N-Assay Pretest Development 1-16-19 posted by Eudius: "The current focus of this NIH grant application is on Group B Streptoccus (GBS). We are currently discussng Urinary Tract Infection (UTI) diagnostic test development with other companies and plan to proceed concurrently with studies for that development .
NanoLogix has also agreed to fund an existing laboratory in Houston currently in use as a clinical laboratory for the medical group associated with Dr Jonathan Faro. This lab will be crucial to the testing of patient samples during the upcoming study.
Although our partner has a very successful record of receiving grants for development, neither NanoLogix nor our partner in the GBS pretest development can guarantee that the NIH grant will be awarded for this project. With that in mind, nanoLogix is continuing to pursue alternative funding for both the GBS and UTI pretest development, including international sale or licensing of the FlatPack extended-life petri plate packaging technology.
Further updates will occur as warranted."
from the below update its apparent the GBS grant was still being pursued.
No mention is made in the last update of the gbs grant,which may or not be instructive.
We know from previous posted dd that its common for grant apps to be rejected the 1st time around in this competitive grant environment and that the applicable NIH committee often makes suggestions to improve the grant proposal.
The 6 month timeline for approval would've been july 2019,at which time the grant may have been approved,and the other items noted in the updates for disclosure have not been completed yet
OR the grant was initially rejected,with the common procedure of the NIH committee suggesting improvements to the proposal,in which case either NNLX and or the CA company are working on the NIH suggested improvements to the proposal
OR the grant was rejected in July and the CA companies cost benefit analysis of their precious time re further pursuit was negative, in which case the CA company working on the GBS grant may have withdrawn. Although the n-assay has much merit, big companies,with sometimes a short attention time and money span,could retire from the situation and thus no mention in the august update- but we dont know this-silence in the last update re this does not necessarily mean this
partly because the net revenue approach is another useful approach,which can be perfectly complementary, just as NNLX said in the 1-19 update, "NanoLogix is continuing to pursue alternative funding for both the GBS and UTI pretest development, including international sale or licensing of the FlatPack extended-life petri plate packaging technology"
and the 8-19 update, "NanoLogix is discussing with domestic and international investment groups, and is seeking additional interested parties."
As I alluded to in a previous post, the new net revenue approach may have more than one purpose,and one of those purposes may be to light a fire(push forward) other negotiations, which may be stalled or stalemated,in order to put pressure on the other party in any such stalled negotiations. I have no inside info re this,but that would be a fairly frequent purpose,which does not take away from the legitimacy of the net revenue approach (a common method) as another realistic avenue to finance the necessary tests.
updates below
Posted On: 04/02/2019 12:44:58 PM
Posted By: Kachingpdx1
Update on N-Assay
Overview and Potential in Multi-billion Diagnostics Market
NanoLogix is pleased to add an important PowerPoint Presentation update to our January 2019 statement of coordinated bacteria pretest development activity with two Biotechnology firms.
Posted On: 08/21/2019 6:53:03 AM
Posted By: willtheoak
like a sleeping purple dinosaur, nanologix has awakened
NanoLogix Seeks $3 Million For Expansion and Development
Offers Net-Revenue Share of N-Assay Bacteria Diagnostic
NanoLogix is discussing with domestic and international investment groups, and is seeking additional interested parties, for an investment offer of a net-revenue interest share of the N-Assay Bacteria Diagnostic and its planned associated Pretest. In exchange for an investment of up to $3 million, NanoLogix proposes a five-year 3-5% net-revenue sharing arrangement beginning with the proposed marketing rollout of the N-Assay in 2021, following planned patient studies in Houston. The funds are to be used for company expansion, development, production and marketing for the N-Assay, Pretest, and FlatPack petri plate technologies. There is no stock issuance or dilution involved with the funding proposal.
A PowerPoint presentation on the N-Assay Bacteria Diagnostic is included to illustrate just some of the advantages of the technology. The PowerPoint includes information on upper respiratory infections (URI), general sepsis infections, and sepsis infections related to infant low-birth weights. In future updates there will be information on shares of the diagnostic market devoted to each of those, and other infections for which configurations of the N-Assay are being explored.
Posted On: 04/02/2019 12:44:58 PM
Posted By: Kachingpdx1
Update on N-Assay
Overview and Potential in Multi-billion Diagnostics Market
NanoLogix is pleased to add an important PowerPoint Presentation update to our January 2019 statement of coordinated bacteria pretest development activity with two Biotechnology firms.
The PowerPoint Presentation can be viewed on The NanoLogix website at: http://nanologix.com/
The purpose of the pre-test use with the N-Assay is to have a pre-test that will indicate the presence of a specific bacteria with minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required.
Further updates will occur as warranted.
Update on N-Assay Pretest Development 1-16-19 posted by Eudius
NIH Grant Application Submitted for
Pre-test Development Study
NanoLogix is pleased to provide this update to our August 2018 statement of coordinated development activity with a California-based Biotechnology firm. The planning for a research study for development of a rapid pre-test for use with the patented Nanologix N-Assay bacteria diagnostic is proceeding, with staff selections completed, letters of recomendation from noted medical authorites written, and the submission last week of the grant application for the study to the NIH by our Silicon-Valley partner. The research study is planned for two major Houston hospitals, funded from both Federal Grants and a raise of investment capital.
The personnel agreeing to participate in the study are seven MDs, two research nurses, two microbiologists, at least two laboratory technicians, and the CEO of the California Biotechnology company. NanoLogix personnel and the CEO of the Biotechnology company have signed a mutual non-disclosure agreement limiting what can presently be revealed but once funding has been obtained and the study registered with the FDA and initiated, the identity of the pre-test development company should be available as public knowledge.
The purpose of the pre-test use with the N-Assay is to have a pre-test that will indicate the presence of a specific bacteria with minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required. This development will significantly reduce reliance upon broad-spectrum antibiotics, which contribute to the major worldwide problem of the development of antibiotic-resistance for many bacteria.
The current focus of this NIH grant application is on Group B Streptoccus (GBS). We are currently discussng Urinary Tract Infection (UTI) diagnostic test development with other companies and plan to proceed concurrently with studies for that development.
NanoLogix has also agreed to fund an existing laboratory in Houston currently in use as a clinical laboratory for the medical group associated with Dr Jonathan Faro. This lab will be crucial to the testing of patient samples during the upcoming study.
Although our partner has a very successful record of receiving grants for development, neither NanoLogix nor our partner in the GBS pretest development can guarantee that the NIH grant will be awarded for this project. With that in mind, nanoLogix is continuing to pursue alternative funding for both the GBS and UTI pretest development, including international sale or licensing of the FlatPack extended-life petri plate packaging technology.
Further updates will occur as warranted.
(3)
(0)